Metabolic syndrome in Sjögren's syndrome patients: a relevant concern for clinical monitoring

详细信息    查看全文

• 作者：Kristopherson Lustosa Augusto ; Eloisa Bonfa…
• 关键词：Adipocytokines ; Cardiovascular risk factors ; Insulin resistance ; Interleukin ; 1beta ; Metabolic syndrome ; Sjögren’s syndrome
• 刊名：Clinical Rheumatology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：35
• 期：3
• 页码：639-647
• 全文大小：317 KB
• 参考文献：1.Mavragani CP, Moutsopoulos HM (2014) Sjögren syndrome. CMAJ 186(15):E579–E586CrossRef PubMed PubMedCentral
  2.Ramos-Casals M, Brito-Zerón P, Kostov B, Sisó-Almirall A, Bosch X, Buss D et al (2015) Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. Autoimmun Rev 14(8):670–679CrossRef PubMed
  3.Roescher N, Tak PP, Illei GG (2009) Cytokines in Sjögren’s syndrome. Oral Dis 15(8):519–526CrossRef PubMed PubMedCentral
  4.Chiorini JA, Cihakova D, Ouellette CE, Caturegli P (2009) Sjögren syndrome: advances in the pathogenesis from animal models. J Autoimmun 33(3–4):190–196CrossRef PubMed PubMedCentral
  5.Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X (2008) B-cell activating factor of the tumor necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren’s syndrome. Scand J Immunol 67(2):185–192CrossRef PubMed
  6.Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, Reddi K et al (2005) Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32(3):435–442PubMed
  7.Sinicato NA, da Silva Cardoso PA, Appenzeller S (2013) Risk factors in cardiovascular disease in systemic lupus erythematosus. Curr Cardiol Rev 9(1):15–19PubMed PubMedCentral
  8.Pereira RM, de Carvalho JF, Bonfá E (2009) Metabolic syndrome in rheumatological diseases. Autoimmun Rev 8(5):415–419CrossRef PubMed
  9.Kaur J (2014) A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014, 943162PubMed PubMedCentral
  10.De Sanctis JB, Zabaleta M, Bianco NE, Garmendia JV, Rivas L (2009) Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity 42(4):272–274CrossRef PubMed
  11.Guzik TJ, Mangalat D, Korbut R (2006) Adipocytokines—novel link between inflammation and vascular function? J Physiol Pharmacol 57(4):505–528PubMed
  12.Ramos-Casals M, Brito-Zerón P, Sisó A, Vargas A, Ros E, Bove A et al (2007) High prevalence of serum metabolic alterations in primary Sjögren’s syndrome: influence on clinical and immunological expression. J Rheumatol 34(4):754–761PubMed
  13.Pérez-De-Lis M, Akasbi M, Sisó A, Diez-Cascon P, Brito-Zerón P, Diaz-Lagares C et al (2010) Cardiovascular risk factors in primary Sjögren’s syndrome: a case–control study in 624 patients. Lupus 19(8):941–948CrossRef PubMed
  14.Juarez M, Toms TE, de Pablo P, Mitchell S, Bowman S, Nightingale P et al (2014) UK Primary Sjögren’s Syndrome Registry. Cardiovascular risk factors in women with primary Sjögren’s syndrome: United Kingdom primary Sjögren’s syndrome registry results. Arthritis Care Res (Hoboken) 66(5):757–764CrossRef
  15.Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F et al. (2015) Cardiovascular disease risk burden in primary Sjögren’s syndrome: results of a population-based multicentre cohort study. J Intern Med 278(2):185--192
  16.Toussirot E, Gaugler B, Bouhaddi M, Nguyen NU, Saas P, Dumoulin G (2010) Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediat Inflamm 2010, 938408CrossRef
  17.Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558CrossRef PubMed PubMedCentral
  18.Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRef PubMed
  19.Ricciardi R (2005) Sedentarism: a concept analysis. Nurs Forum 40(3):79–87CrossRef PubMed
  20.Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E et al (2010) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 69(6):1103–1109CrossRef PubMed PubMedCentral
  21.Vandermeersch A, Ameye S, Puype D, Petitjean D, De Buyzere M, Langlois MR (2010) Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment. Clin Chim Acta 411(17–18):1361–1366CrossRef PubMed
  22.Szodoray P, Alex P, Brun JG, Centola M, Jonsson R (2004) Circulating cytokines in primary Sjögren’s syndrome determined by a multiplex cytokine array system. Scand J Immunol 59(6):592–599CrossRef PubMed
  23.Liu MY, Xydakis AM, Hoogeveen RC, Jones PH, Smith EO, Nelson KW et al (2005) Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem 51(7):1102–1109CrossRef PubMed
  24.Ozgen M, Koca SS, Aksoy K, Dagli N, Ustundag B, Isik A (2011) Visfatin levels and intima-media thicknesses in rheumatic diseases. Clin Rheumatol 30(6):757–763CrossRef PubMed
  25.Borai A, Livingstone C, Kaddam I, Ferns G (2011) Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol 11:158CrossRef PubMed PubMedCentral
  26.Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27(10):2444–2449CrossRef PubMed
  27.Cameron AJ, Shaw JE, Zimmet PZ (2006) The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33(2):351–375CrossRef
  28.Polotsky HN, Polotsky AJ (2010) Metabolic implications of menopause. Semin Reprod Med 28(5):426–434CrossRef PubMed
  29.Sabio JM, Sánchez-Berná I, Martinez-Bordonado J, Vargas-Hitos JA, Navarrete-Navarrete N, Expósito Ruíz M et al (2015) Prevalence of and factors associated with increased arterial stiffness in patients with primary Sjögren’s syndrome. Arthritis Care Res (Hoboken) 67(4):554–562CrossRef
  30.Zardi EM, Sambataro G, Basta F, Margiotta DP, Afeltra AM (2014) Subclinical carotid atherosclerosis in elderly patients with primary Sjögren syndrome: a duplex Doppler sonographic study. Int J Immunopathol Pharmacol 27(4):645–651PubMed
  31.Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D et al (2015) Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren’s syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther 17(1):99CrossRef PubMed PubMedCentral
  32.Chiang CH, Liu CJ, Chen PJ, Huang CC, Hsu CY, Chan WL et al (2014) Primary Sjögren’s syndrome and risk of ischemic stroke: a nationwide study. Clin Rheumatol 33(7):931–937CrossRef PubMed
  33.Parker B, Ahmad Y, Shelmerdine J, Edlin H, Yates AP, Teh LS et al (2011) An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 20(14):1459–1465CrossRef PubMed
  34.Negrón AM, Molina MJ, Mayor AM, Rodríguez VE, Vilá LM (2008) Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus 17(4):348–354CrossRef PubMed PubMedCentral
  35.Chen X, Devaraj S (2014) Monocytes from metabolic syndrome subjects exhibit a proinflammatory M1 phenotype. Metab Syndr Relat Disord 12(7):362–366CrossRef PubMed
  36.Cojocaru M, Cojocaru IM, Silosi I, Rogoz S (2013) Role of leptin in autoimmune diseases. Maedica (Buchar) 8(1):61–74
  37.Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334(5):292–295CrossRef PubMed
  38.Guo H, Callaway JB, Ting JP (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21(7):677–687CrossRef PubMed
  39.Baldini C, Rossi C, Ferro F, Santini E, Seccia V, Donati V et al (2013) The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren’s syndrome. J Intern Med 274(5):480–489CrossRef PubMed
  40.Norheim KB, Harboe E, Gøransson LG, Omdal R (2012) Interleukin-1 inhibition and fatigue in primary Sjögren’s syndrome—a double blind, randomised clinical trial. PLoS One 7(1), e30123CrossRef PubMed PubMedCentral
  41.García-Cáceres C, Fuente-Martín E, Díaz F, Granado M, Argente-Arizón P, Frago LM et al (2014) The opposing effects of ghrelin on hypothalamic and systemic inflammatory processes are modulated by its acylation status and food intake in male rats. Endocrinology 155(8):2868–2880CrossRef PubMed
  42.Bichile T, Petri M (2014) Prevention and management of co-morbidities in SLE. Presse Med 43(6 Pt 2):e187–e195CrossRef PubMed
  43.Krysiak R, Handzlik-Orlik G, Okopien B (2012) The role of adipokines in connective tissue diseases. Eur J Nutr 51(5):513–528CrossRef PubMed PubMedCentral
  44.Boström EA, d’Elia HF, Dahlgren U, Simark-Mattsson C, Hasséus B, Carlsten H et al (2008) Salivary resistin reflects local inflammation in Sjögren’s syndrome. J Rheumatol 35(10):2005–2011PubMed
  45.Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7):932–939CrossRef PubMed
  
• 作者单位：Kristopherson Lustosa Augusto (1)
  Eloisa Bonfa (1)
  Rosa Maria Rodrigues Pereira (1)
  Cleonice Bueno (1)
  Elaine Pires Leon (1)
  Vilma Santos Trindade Viana (1)
  Sandra Gofinet Pasoto (1) (2)
  
  1. Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP), São Paulo, Brazil
  2. Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo, 455, 3° andar (Disciplina de Reumatologia), sala 3192, Cerqueira César, São Paulo, SP, ZIP code 01246-903, Brazil
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  
• 出版者：Springer London
• ISSN：1434-9949

文摘

Metabolic syndrome (MetS) has been described in autoimmune diseases. However, there are scarce data about MetS and adipocytokine profile in primary Sjögren’s syndrome (pSS). Seventy-one female pSS patients (American-European Consensus Group Criteria, 2002) aged 18–65 years and 71 age-, race-matched control women were enrolled in this case–control study. Clinical data were collected by a standardized protocol. Blood levels of glucose, cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglycerides, interleukin-1beta (IL-1beta)/IL-6, B-cell activating factor (BAFF), insulin, and leptin/adiponectin/visfatin/resistin were determined. Patients and controls were comparable regarding body mass index (BMI), smoking, sedentariness, and menopause (p > 0.05). MetS (39.4 vs. 16.9 %, p = 0.005), hypertension (p = 0.004), and dyslipidemia (p = 0.002) were more frequent in patients than controls. IL-1beta, IL-6, BAFF, resistin, and adiponectin levels were higher in patients than controls (p < 0.05). pSS patients with MetS (n = 28) had higher BMI, waist circumference, cholesterol, LDL-C, triglycerides, insulin, leptin and HOMA-IR values, and greater hypertension and diabetes rates than pSS patients without MetS (n = 43) (p < 0.05). Current and/or previous prednisone use (75.0 vs. 62.8 %, p = 0.313), current (3.0 ± 4.5 vs. 1.6 ± 3.2 mg/day, p = 0.299), and cumulative prednisone doses (p = 0.495) were similar in both groups. Otherwise, IL-1beta level was higher in MetS patients than in non-MetS patients (p = 0.012), and this finding was confirmed (p = 0.048) by multivariate analysis with adjustments for age, ethnicity, prednisone use, current and cumulative prednisone doses, and duration of use. We identified high MetS frequency and abnormal adipocytokine profile in pSS. The association of MetS with elevated IL-1beta level suggests that inflammation plays an important role in its pathogenesis.